Blueprint Medicines (BPMC) Company Report

Blueprint Medicines Corporation (BPMC) completed its merger with Rothko Merger Sub, Inc., a wholly owned subsidiary of SANOFI's Aventis Inc., on July 17, 2025.
The acquisition was structured as a tender offer, with shareholders receiving $129.00 per Share in cash plus one non-transferable contractual contingent value right (CVR) per Share.
Each CVR represents the right to receive contingent payments of up to an aggregate amount of $6.00 per Share in cash upon the achievement of specified milestones.
The aggregate cash consideration paid by the Purchaser for the shares in the offer and merger was approximately $9.1 billion.
As a result of the merger, BPMC became a wholly owned subsidiary of Aventis, and its shares will be delisted from Nasdaq.

Jul 18, 2025, 12:00 AM

Blueprint Medicines presents long-term AYVAKIT data at 2025 EHA and EAACI congresses

BPMC

Blueprint Medicines showcased a decade of collaboration and data presentations for AYVAKIT®/AYVAKYT® at the 2025 EHA and EAACI congresses, emphasizing its role as a durable standard of care in both indolent and advanced systemic mastocytosis.
PIONEER three-year results demonstrated sustained symptom improvements through 144 weeks, with a 3 % discontinuation rate due to treatment-related adverse events and a median exposure of three years (some patients treated up to five years).
PATHFINDER and EXPLORER multi-year analyses showed prolonged overall survival with AYVAKIT versus real-world midostaurin data across all risk categories, validated by the new MARS-R prognostic tool.
PRISM survey data highlighted the substantial real-world burden of indolent systemic mastocytosis on patients’ physical, social and emotional well-being.

Jun 12, 2025, 10:01 PM

Blueprint Medicines Acquisition Announced by Sanofi

BPMC

M&A

Sanofi announced it will acquire Blueprint Medicines to expand its portfolio in rare immunological diseases and boost its early-stage immunology pipeline.
The acquisition includes Blueprint’s approved Ayvakit/Ayvakyt for systemic mastocytosis and advanced candidates like elenestinib and BLU‑808.
The deal terms feature a cash offer of $129.00 per share (totaling approximately $9.1 billion) plus contingent value rights for potential milestone payments.

Jun 2, 2025, 12:00 AM

Blueprint Medicines Q1 2025 Earnings & Clinical Update

BPMC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Q1 2025 net product revenues reached $149.4M from AYVAKIT/AYVAKYT sales—including $129.4M in the U.S.—with 61% YoY growth .
Raised full-year AYVAKIT net product revenue guidance to $700–$720M, supporting a longer-term target of $2B by 2030 .
Robust growth in patient starts and prescriber expansion driven by targeted allergist initiatives and plans to expand into dermatology and gastroenterology .
Clinical progress includes advancement in the HARBOR study of elenestinib and initiation of BLU-808 proof-of-concept studies for allergic rhinoconjunctivitis and chronic urticaria, with a sustained favorable safety profile over three years .
Demonstrated a strong balance sheet with an approximate cash position of $900M, including a $78.7M boost from an equity investment sale .

May 1, 2025, 12:01 PM

Blueprint Medicines Showcases Mast Cell Therapy Data at AAAAI/WAO Joint Congress

BPMC

New Projects/Investments

AYVAKIT demonstrated strong long-term efficacy and safety in ISM with three-year follow-up data from the PIONEER trial, showing durable symptom improvement and positive effects on bone health.
BLU-808 displayed a wide therapeutic window and favorable tolerability in Phase 1 trials, supporting its potential as a first-in-class oral wild-type KIT inhibitor.

Feb 28, 2025, 1:00 PM

Blueprint Medicines Q4 & FY2024 Results with 2025 Guidance & Strategic Updates

BPMC

Earnings

Guidance Update

Revenue Acceleration/Inflection

Q4 2024 & FY2024 Performance: Reported Q4 total revenue of $146.4M (with $144.1M in net product sales and a $50.0M net loss) and full-year revenue of $508.8M.
AYVAKIT Growth: Achieved $479.0M in net product revenues in 2024 (including $144.1M in Q4) with 135% YoY growth, driven by strong performance in both US and ex‑US markets.
2025 Guidance: Expects global AYVAKIT revenues of $680–710M (approx. 45% YoY growth) with a long-term target of $2B by 2030, alongside an updated systemic mastocytosis franchise peak opportunity of $4B.
Strategic & Clinical Updates: Highlighted the presentation of 14 abstracts at major conferences, promising Phase 1 healthy volunteer data for BLU-808, and increased investments in R&D, SG&A, commercial infrastructure, and field team expansion supported by a robust cash position of $864M and reduced operating cash burn.

Feb 13, 2025, 12:00 PM

Filings & Transcripts

Recent SEC filings and earnings call transcripts for BPMC.

No recent filings or transcripts found for BPMC.